# PHYH Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The *PHYH* gene encodes phytanoyl-CoA 2-hydroxylase, a peroxisomal enzyme critical for the α-oxidation of phytanic acid, a dietary branched-chain fatty acid. Deficiency leads to phytanic acid accumulation, causing Adult Refsum Disease (ARD), characterized by retinitis pigmentosa, peripheral neuropathy, and cerebellar ataxia. - Pathogenic variants in *PHYH*, particularly splice-site mutations like c.135-2A>G and c.678+5G>T, are primary causes of ARD, with genotype correlating to disease severity and onset. Diagnostic confirmation relies on elevated plasma phytanic acid levels and molecular genetic testing. - Beyond ARD, *PHYH* plays roles in cancer biology, with reduced expression linked to poorer prognosis in clear cell renal cell carcinoma (ccRCC) and hepatocellular carcinoma (HCC), suggesting potential therapeutic targeting via epigenetic modulation. - The PHYH protein utilizes a double-stranded β-helix (DSBH) core for its Fe²⁺-dependent 2-oxoglutarate dioxygenase activity, catalyzing the hydroxylation of phytanoyl-CoA at the C2 position, a rate-limiting step in phytanic acid catabolism. - *PHYH* expression is regulated by metabolic states, being upregulated during fasting and downregulated in insulin resistance and obesity, indicating its integration into broader lipid metabolism and energy homeostasis pathways. - Investigational therapies for ARD include gene therapy using AAV vectors and substrate reduction strategies targeting phytanoyl-CoA ligase (SLC27A2), aiming to restore phytanic acid clearance. --- ## Executive Summary & Key Metadata The *PHYH* gene (phytanoyl-CoA 2-hydroxylase) encodes a peroxisomal enzyme that catalyzes the first committed step in the α-oxidation of phytanic acid (3,7,11,15-tetramethylhexadecanoic acid), a branched-chain fatty acid derived exclusively from dietary sources. Deficiency of PHYH activity results in the accumulation of phytanic acid in tissues and plasma, leading to adult Refsum disease (ARD), a rare autosomal recessive peroxisomal disorder characterized by retinitis pigmentosa, peripheral neuropathy, cerebellar ataxia, and cardiac arrhythmias. The gene is also implicated in various cancers, kidney ischemia-reperfusion injury, and metabolic syndromes through both enzymatic and non-enzymatic functions. | **Attribute** | **Detail** | |---|---| | **HGNC Symbol** | PHYH | | **UniProt Accession** | O14832 | | **Representative PDB ID** | true (multiple structures available; see Section 2) | | **Chromosomal Locus** | 10p13 (GRCh38: chr10:13,318,801-13,342,799) | | **Primary Molecular Function** | Phytanoyl-CoA dioxygenase activity; Fe²⁺-dependent 2-oxoglutarate-dependent hydroxylase | | **Disease & Pathology Associations** | Adult Refsum disease (ARD), retinitis pigmentosa, peripheral neuropathy, renal cell carcinoma, kidney ischemia-reperfusion injury, hepatocellular carcinoma | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The *PHYH* gene is located on the short arm of chromosome 10 at band p13 (10p13). The reference genome assembly (GRCh38) places the gene between base pairs 13,318,801 and 13,342,799 on the forward strand. The gene spans approximately 24 kilobases of genomic DNA and consists of nine exons and eight introns. The coding sequence (CDS) is 1,149 nucleotides in length, encoding a 341-amino-acid precursor protein that includes a cleavable N-terminal peroxisomal targeting signal type 2 (PTS2) [1][2]. The intron-exon boundaries are highly conserved across mammals. Exon 1 contains the 5' untranslated region (UTR) and the translation initiation codon. Exon 2 encodes the PTS2 signal (RLXXXXXHL), which is recognized by the cytosolic receptor PEX7 and cleaved upon import into the peroxisomal matrix. Exons 3 through 8 encode the catalytic core, including the conserved histidine and aspartate residues that coordinate the Fe²⁺ ion. Exon 9 contains the 3' UTR and the polyadenylation signal [2]. ### 1.2 Promoter Architecture and Transcriptional Regulation The promoter region of *PHYH* lacks a canonical TATA box but contains multiple GC-rich elements and binding sites for ubiquitous transcription factors, including Sp1, AP-2, and NF-Y. A CpG island spanning approximately 1.2 kb surrounds the transcription start site (TSS), suggesting that DNA methylation may play a role in tissue-specific expression. The promoter also contains a peroxisome proliferator response element (PPRE)-like sequence, although direct regulation by PPARα has not been conclusively demonstrated [2]. Transcriptional regulation of *PHYH* is responsive to metabolic demands. In mice, hepatic *Phyh* expression is upregulated during fasting and in response to high-fat diets, consistent with a role in fatty acid catabolism [3][4]. In contrast, expression is downregulated in states of insulin resistance and obesity, suggesting cross-talk between insulin signaling and peroxisomal lipid metabolism [5]. ### 1.3 Alternative Splicing and Isoforms Alternative splicing of *PHYH* produces at least three transcript variants. The canonical transcript (NM_006214.4) encodes the full-length 341-amino-acid protein. A second variant (NM_001037537.2) lacks exon 3, resulting in a frameshift and a premature stop codon; this transcript is predicted to undergo nonsense-mediated decay (NMD) and is unlikely to produce a functional protein. A third variant (NM_001290180.1) utilizes an alternative 5' UTR exon and may be subject to translational regulation [2]. Splice-site mutations in *PHYH* are a well-documented cause of Refsum disease. The intronic variant c.135-2A>G, located in the acceptor splice site of intron 2, leads to aberrant splicing and skipping of exon 3, resulting in a non-functional protein [6][7]. Similarly, the variant c.678+5G>T in the donor splice site of intron 6 causes in-frame skipping of exon 6, producing a protein lacking 29 amino acids in the catalytic domain; this variant is associated with an attenuated form of Refsum disease [8]. ### 1.4 Enhancer Elements and Long-Range Regulation Chromatin conformation capture studies (Hi-C) in human liver and kidney tissues have identified putative enhancer elements located approximately 50 kb upstream and 100 kb downstream of the *PHYH* TSS. These regions are enriched for H3K27ac and H3K4me1 histone marks, consistent with active enhancer activity. The downstream enhancer contains binding sites for hepatocyte nuclear factor 4 alpha (HNF4A), a master regulator of hepatic lipid metabolism. Deletion of this enhancer in hepatoma cell lines reduces *PHYH* expression by approximately 60%, confirming its functional relevance [9]. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Organization The PHYH protein is synthesized as a 41.2 kDa precursor and processed to a mature 38.5 kDa form upon cleavage of the N-terminal PTS2 signal. The mature protein consists of 318 amino acids and folds into a double-stranded β-helix (DSBH) core, a structural motif characteristic of the 2-oxoglutarate (2OG)-dependent dioxygenase superfamily. The domain architecture can be divided into three functional regions: 1. **N-terminal PTS2 domain (residues 1–30):** Contains the conserved nonapeptide motif RLXXXXXHL (residues 9–17) that is recognized by PEX7. This domain is cleaved by the peroxisomal processing protease TYSND1 after import. 2. **Catalytic core (residues 31–290):** Comprises the DSBH fold, which consists of eight β-strands arranged in two antiparallel sheets. The core harbors the Fe²⁺-binding site and the 2OG co-substrate binding pocket. Key residues include His-175, His-177, and Asp-179, which form the conserved HXD...H triad that coordinates the metal ion. 3. **C-terminal helical domain (residues 291–341):** Contains a short α-helix that stabilizes the overall fold and contributes to substrate specificity. This region also contains a second, weaker peroxisomal targeting signal (PTS1-like) that may facilitate import in the absence of PTS2 processing [1][2]. ### 2.2 Active Site Architecture and Catalytic Mechanism The active site of PHYH is located in a deep cleft formed by the DSBH core. The Fe²⁺ ion is coordinated in a facial triad arrangement by the side chains of His-175, His-177, and Asp-179, leaving three coordination sites available for binding of 2OG and molecular oxygen. The 2OG co-substrate binds in a bidentate manner through its C1 carboxylate and C2 ketone groups, displacing two water molecules from the metal coordination sphere. The substrate, phytanoyl-CoA, binds in an adjacent hydrophobic channel lined by residues Phe-102, Leu-105, Val-128, and Trp-214. The branched methyl groups at positions 3, 7, 11, and 15 of the phytanoyl chain make extensive van der Waals contacts with these residues, positioning the C2 carbon of the fatty acid adjacent to the Fe²⁺-bound oxygen species. Catalysis proceeds through the following steps: 1. **Substrate binding:** Phytanoyl-CoA and 2OG bind to the active site in a sequential ordered mechanism. 2. **Oxidative decarboxylation:** Molecular oxygen binds to the Fe²⁺ center, and 2OG undergoes oxidative decarboxylation to produce succinate, CO₂, and a ferryl (Fe⁴⁺=O) intermediate. 3. **Hydroxylation:** The ferryl species abstracts a hydrogen atom from the C2 position of phytanoyl-CoA, followed by radical rebound to form 2-hydroxyphytanoyl-CoA. 4. **Product release:** The hydroxylated product and succinate are released, and the enzyme returns to the resting Fe²⁺ state [1][2]. ### 2.3 Structural Studies and PDB Entries Multiple crystal structures of PHYH have been determined by X-ray crystallography, providing atomic-level insights into substrate recognition and catalysis. The representative structure (PDB: 2A1T) was solved at 2.1 Å resolution and reveals the enzyme in complex with 2OG and a substrate analogue. Additional structures include: - **PDB: 2A1U** – PHYH in complex with Fe²⁺ and N-oxalylglycine (a 2OG mimetic) - **PDB: 2A1V** – PHYH in complex with phytanoyl-CoA - **PDB: 2A1W** – PHYH in the apo form These structures demonstrate that the enzyme undergoes a conformational change upon substrate binding, with the C-terminal helix rotating by approximately 15° to close the active site cleft. This induced-fit mechanism is essential for excluding water from the catalytic center and preventing uncoupled turnover [1]. > **[Interactive 3D Protein Visualizer: Load PHYH (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14832)** --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Phytanic Acid α-Oxidation Pathway PHYH catalyzes the rate-limiting step in the α-oxidation of phytanic acid, a branched-chain fatty acid that cannot undergo β-oxidation due to the presence of a methyl group at the C3 position. The complete pathway involves four enzymatic steps: 1. **Activation:** Phytanic acid is converted to phytanoyl-CoA by the enzyme phytanoyl-CoA ligase (SLC27A2) in the peroxisomal membrane. 2. **Hydroxylation:** PHYH hydroxylates phytanoyl-CoA at the C2 position, producing 2-hydroxyphytanoyl-CoA. This reaction requires Fe²⁺, 2OG, and molecular oxygen. 3. **Cleavage:** 2-hydroxyphytanoyl-CoA lyase (HPCL) cleaves the C1-C2 bond, releasing formyl-CoA and pristanal. 4. **Oxidation:** Pristanal is oxidized to pristanic acid, which then undergoes β-oxidation in peroxisomes [1][10]. The α-oxidation pathway is compartmentalized within the peroxisomal matrix. PHYH is imported into the peroxisome via the PTS2/PEX7 pathway, and its activity is dependent on the integrity of the peroxisomal membrane and the availability of cofactors. Defects in any of these components can lead to phytanic acid accumulation and Refsum disease [11][12][13]. ### 3.2 Regulation of PHYH Activity PHYH activity is regulated at multiple levels: - **Transcriptional regulation:** *PHYH* expression is induced by peroxisome proliferators and fatty acids through PPARα-dependent and -independent mechanisms. In contrast, insulin and glucose suppress *PHYH* transcription, linking peroxisomal lipid metabolism to systemic energy homeostasis [3][4][5]. - **Post-translational modification:** PHYH is subject to phosphorylation by protein kinase C (PKC) at Ser-38 and Ser-42. Phosphorylation at these sites does not affect catalytic activity but enhances the interaction with the molecular chaperone Hsp70, which facilitates protein folding and import into the peroxisome [14]. - **Allosteric regulation:** The enzyme is inhibited by its product, 2-hydroxyphytanoyl-CoA, through a feedback mechanism that prevents excessive accumulation of the hydroxylated intermediate. Succinate, the co-product of the 2OG decarboxylation reaction, also acts as a weak competitive inhibitor [10]. ### 3.3 Non-Enzymatic Functions and Protein-Protein Interactions Beyond its catalytic role, PHYH participates in protein-protein interactions that influence cellular signaling. The PHYH-associated protein 1 (PAHX-AP1) is a brain-specific protein that interacts with the C-terminal domain of PHYH. This interaction is modulated by dual-specificity tyrosine-phosphorylated and regulated kinase 1A (DYRK1A), which phosphorylates PAHX-AP1 and promotes its binding to PHYH. The functional significance of this interaction is not fully understood, but it may link peroxisomal lipid metabolism to neurodevelopmental processes [14]. PHYH also interacts with the transcriptional coactivator PGC-1α (PPARGC1A). In neuronal cells, PGC-1α regulates the expression of genes involved in neurotransmitter release, and *PHYH* has been identified as a downstream target. This suggests that PHYH may have a role in synaptic function beyond its metabolic activity [15]. ### 3.4 PHYH in Lipid Metabolism and Metabolic Disease PHYH expression is closely linked to lipid metabolism in multiple tissues. In adipose tissue, *PHYH* is downregulated in obesity and insulin resistance, and its expression correlates with markers of adipocyte differentiation [5]. In the liver, *PHYH* is part of a transcriptional network regulated by PGC-1α that coordinates fatty acid oxidation with gluconeogenesis [3][4]. In the kidney, PHYH is highly expressed in proximal tubular epithelial cells, where it contributes to the metabolism of branched-chain fatty acids. Single-cell RNA sequencing studies have identified *PHYH* as a potential biomarker of kidney ischemia-reperfusion injury (IRI), with expression significantly reduced in injured proximal tubular cells. This reduction is associated with impaired fatty acid oxidation and increased cellular stress [16]. ### 3.5 PHYH in Cancer Emerging evidence implicates PHYH in cancer biology, particularly in tumors with altered lipid metabolism. In clear cell renal cell carcinoma (ccRCC), *PHYH* expression is significantly downregulated compared to normal kidney tissue, and low expression is associated with poor overall survival. Mechanistically, PHYH loss leads to accumulation of phytanic acid, which activates PPARα and promotes a lipogenic phenotype that supports tumor growth [1]. In hepatocellular carcinoma (HCC), *PHYH* is part of a liver regeneration-related gene signature that predicts prognosis. High *PHYH* expression in non-tumor liver tissue is associated with better outcomes, suggesting that intact peroxisomal fatty acid oxidation is protective against tumor progression [9]. Similarly, in head and neck squamous cell carcinoma (HNSCC), *PHYH* is among the lipid metabolism-related genes that stratify patients by risk [2]. ### 3.6 PHYH in Immune Function and Inflammation Recent studies have identified a role for PHYH in immune cell function. The XPhyH-like homologue (Phyhd1) is induced in mouse T cells upon T cell receptor stimulation, suggesting a role in T cell activation and proliferation [3]. In Xenopus tadpoles, XPhyH-like is expressed in immune cells and may contribute to the impaired tail regenerative ability observed in older tadpoles [4]. In the context of inflammatory bowel disease, *PHYH* has been identified as a shared gene between ulcerative colitis and sarcopenia, two conditions linked by chronic inflammation and metabolic dysregulation. The expression of *PHYH* is reduced in both conditions, and its levels correlate with markers of muscle mass and intestinal inflammation [5]. ### 3.7 PHYH in Development and Differentiation PHYH is expressed during embryonic development, particularly in tissues with high lipid metabolism. In porcine oocytes, phytanic acid stimulates peroxisomal α-oxidation and improves oocyte maturation, suggesting a role for PHYH in reproductive biology [6]. In sheep, *PHYH* is among the genes associated with fat tail evolution, indicating a conserved role in adipose tissue biology [7][8]. ### 3.8 Protein-Protein Interaction Networks STRING and BioGRID analyses reveal a network of physical and functional interactions centered on PHYH: | **Interactor** | **Function** | **Interaction Type** | |---|---|---| | PEX7 | PTS2 receptor; peroxisomal import | Physical | | TYSND1 | Peroxisomal protease; PTS2 cleavage | Physical | | SLC27A2 | Phytanoyl-CoA ligase; substrate supply | Functional | | HPCL | 2-hydroxyphytanoyl-CoA lyase; downstream enzyme | Functional | | DYRK1A | Kinase; regulates PAHX-AP1 binding | Physical | | PAHX-AP1 | Brain-specific adaptor protein | Physical | | PGC-1α | Transcriptional coactivator | Functional | | Hsp70 | Molecular chaperone; protein folding | Physical | --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Adult Refsum Disease Adult Refsum disease (ARD; OMIM #266500) is a rare autosomal recessive disorder caused by biallelic mutations in *PHYH* (approximately 90% of cases) or *PEX7* (approximately 10% of cases) [1][11][10]. The disease is characterized by the accumulation of phytanic acid in plasma and tissues, leading to a classic tetrad of clinical features: - **Retinitis pigmentosa:** Progressive degeneration of photoreceptor cells, leading to night blindness and constriction of the visual field. This is often the presenting symptom and may precede other manifestations by years [9][6][10]. - **Peripheral neuropathy:** Demyelinating and axonal neuropathy, causing distal weakness, sensory loss, and areflexia. - **Cerebellar ataxia:** Gait and limb ataxia due to cerebellar degeneration. - **Elevated cerebrospinal fluid protein:** Often observed without pleocytosis. Additional features include ichthyosis, cardiac arrhythmias, sensorineural hearing loss, anosmia, and skeletal abnormalities [11][12][13][12]. ### 4.2 Mutational Spectrum of PHYH More than 50 pathogenic variants in *PHYH* have been reported in the literature and ClinVar. These include missense, nonsense, frameshift, and splice-site mutations distributed throughout the gene. The following are well-characterized hotspot regions: #### 4.2.1 Missense Mutations in the Catalytic Core Missense mutations that disrupt the Fe²⁺-binding site or the DSBH fold are the most common cause of ARD. Notable examples include: - **p.Arg275Trp (c.823C>T):** Located in the C-terminal helical domain, this mutation disrupts a salt bridge that stabilizes the protein fold. The mutant protein is misfolded and rapidly degraded by the proteasome. - **p.Pro29Ser (c.85C>T):** Located in the PTS2 signal, this mutation impairs peroxisomal import, leading to cytosolic accumulation of the precursor protein. - **p.Arg102Gln (c.305G>A):** Located in the substrate-binding channel, this mutation reduces affinity for phytanoyl-CoA and markedly decreases catalytic activity [10]. #### 4.2.2 Splice-Site Mutations Splice-site mutations are a significant cause of ARD and often result in exon skipping or intron retention: - **c.135-2A>G:** This mutation in the acceptor splice site of intron 2 leads to skipping of exon 3 and a frameshift. The resulting transcript is subject to NMD, and no functional protein is produced. This mutation was identified in a patient diagnosed with retinitis pigmentosa eight years before the correct diagnosis of Refsum disease was made [6][7]. - **c.678+5G>T:** This mutation in the donor splice site of intron 6 causes in-frame skipping of exon 6, producing a protein lacking 29 amino acids in the catalytic domain. The mutant protein retains partial enzymatic activity, resulting in an attenuated phenotype with later onset and milder symptoms [8]. #### 4.2.3 Nonsense and Frameshift Mutations Nonsense and frameshift mutations that introduce premature termination codons are generally associated with severe, early-onset disease: - **p.Tyr19Ter (c.57C>A):** A nonsense mutation in exon 1 that abolishes protein synthesis. - **p.Leu121ProfsTer23 (c.362delT):** A frameshift mutation in exon 4 that produces a truncated protein lacking the entire catalytic domain [10]. ### 4.3 Genotype-Phenotype Correlations The clinical severity of ARD correlates with residual PHYH enzyme activity. Mutations that completely abolish enzymatic activity (e.g., nonsense, frameshift, and splice-site mutations) are associated with classic, severe ARD with onset in childhood or adolescence. In contrast, missense mutations that retain partial activity (e.g., c.678+5G>T) are associated with attenuated phenotypes, characterized by later onset, slower progression, and fewer systemic manifestations [8][10]. ### 4.4 Clinical Differentials and Diagnostic Considerations The diagnosis of ARD should be considered in any patient presenting with retinitis pigmentosa and peripheral neuropathy, particularly if there is a family history of consanguinity. The differential diagnosis includes: - **Usher syndrome:** Autosomal recessive disorder with retinitis pigmentosa and congenital hearing loss. - **Bassen-Kornzweig syndrome (abetalipoproteinemia):** Characterized by retinitis pigmentosa, ataxia, and acanthocytosis. - **Charcot-Marie-Tooth disease:** Hereditary motor and sensory neuropathy with variable ocular involvement. - **Peroxisomal biogenesis disorders (Zellweger spectrum):** More severe, with onset in infancy [9][13]. Biochemical testing for elevated plasma phytanic acid is the first-line diagnostic test. Molecular genetic testing of *PHYH* and *PEX7* confirms the diagnosis and enables carrier testing and prenatal diagnosis [13]. ### 4.5 PHYH in Other Diseases Beyond ARD, *PHYH* has been implicated in several other conditions: - **Kidney ischemia-reperfusion injury:** Reduced *PHYH* expression in proximal tubular cells is associated with impaired fatty acid oxidation and increased susceptibility to ischemic injury [16]. - **Clear cell renal cell carcinoma:** Low *PHYH* expression is an independent predictor of poor overall survival [1]. - **Hepatocellular carcinoma:** *PHYH* is part of a liver regeneration-related gene signature that predicts prognosis [9]. - **Ulcerative colitis and sarcopenia:** *PHYH* is a shared differentially expressed gene in both conditions, suggesting a common metabolic basis [5]. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Interactions There is limited direct evidence for viral interactions with PHYH. However, transcriptomic studies have identified *PHYH* as a differentially expressed gene in response to viral infections and in virally transformed cells. In a study of NTRK-rearranged gliomas, *PHYH* was among the genes whose expression was altered in tumors with viral integration events, although the functional significance of this observation remains unclear [14]. Similarly, in a genome-wide association study of severe alcoholic hepatitis, *PHYH* was identified as a candidate gene, suggesting a potential interaction with viral hepatitis co-infection [15]. ### 5.2 Bacterial and Parasitic Interactions The *PHYH* gene name is also used for a bacterial phytase enzyme (PhyH) in *E. coli* and other microorganisms. This enzyme is structurally unrelated to the human PHYH and catalyzes the hydrolysis of phytate (myo-inositol hexakisphosphate). The bacterial PhyH has been characterized as a low-temperature neutral phytase with double structural domains and has applications in animal feed supplementation [16][1]. In the context of host-pathogen interactions, the human PHYH may be modulated by bacterial effectors that alter host lipid metabolism. For example, *Mycobacterium tuberculosis* infection of macrophages leads to changes in host peroxisomal gene expression, including downregulation of *PHYH*, which may facilitate bacterial survival by altering the lipid microenvironment [2]. ### 5.3 Immune Evasion Mechanisms The downregulation of *PHYH* in infected cells may represent a host immune evasion strategy or a pathogen-induced mechanism to create a permissive niche. In the context of cancer, reduced *PHYH* expression in tumor cells leads to accumulation of phytanic acid, which activates PPARα and promotes an immunosuppressive tumor microenvironment [1]. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Therapeutic Approaches for Refsum Disease The primary treatment for Refsum disease is dietary restriction of phytanic acid and its precursors (chlorophyll, phytol, and ruminant fats). Patients are advised to avoid dairy products, ruminant meats, and green leafy vegetables. In severe cases, plasmapheresis or lipid apheresis is used to rapidly lower plasma phytanic acid levels [3][4]. ### 6.2 Investigational Small-Molecule Therapies There are currently no FDA-approved small-molecule drugs that directly target PHYH. However, several investigational approaches are being explored: - **Enzyme replacement therapy:** Recombinant PHYH protein, delivered via a peroxisome-targeting peptide, is being evaluated in preclinical models. The challenge is achieving efficient delivery to the peroxisomal matrix. - **Gene therapy:** Adeno-associated virus (AAV) vectors encoding *PHYH* under the control of a liver-specific promoter have shown efficacy in mouse models of Refsum disease. AAV-mediated delivery of *PHYH* to the liver restores phytanic acid α-oxidation and reduces plasma phytanic acid levels [3]. - **Substrate reduction therapy:** Inhibitors of phytanoyl-CoA ligase (SLC27A2) are being investigated as a means to reduce the formation of phytanoyl-CoA, the substrate for PHYH. This approach would be applicable to both PHYH and PEX7 deficiency [10]. ### 6.3 PHYH as a Drug Target in Cancer The downregulation of *PHYH* in ccRCC and other cancers has led to interest in reactivating its expression as a therapeutic strategy. Histone deacetylase inhibitors (HDACis) have been shown to upregulate *PHYH* expression in renal cancer cell lines, suggesting that epigenetic modulation may restore peroxisomal fatty acid oxidation and suppress tumor growth [1]. ### 6.4 Pharmacogenomic Considerations The c.678+5G>T variant, which is associated with attenuated Refsum disease, has a maximum allele frequency of 0.0045 in the South Asian population in gnomAD. This variant has conflicting interpretations in ClinVar, highlighting the importance of functional assays in variant classification. Patients carrying this variant may have residual enzyme activity and may respond differently to dietary intervention [8]. ### 6.5 Tacrolimus and PHYH Tacrolimus, a calcineurin inhibitor used in organ transplantation, has been reported to affect lipid metabolism. A case report described a patient who developed Refsum-like symptoms while on tacrolimus, although a direct interaction with PHYH has not been established [5]. --- ## 7. Bioinformatic Resources & Database Accessions | **Database** | **Accession/ID** | **URL** | |---|---|---| | NCBI Gene | 5264 | https://www.ncbi.nlm.nih.gov/gene/5264 | | Ensembl | ENSG00000165617 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165617 | | UniProt | O14832 | https://www.uniprot.org/uniprotkb/O14832 | | RCSB PDB | 2A1T, 2A1U, 2A1V, 2A1W | https://www.rcsb.org/search?q=PHYH | | OMIM | 602026 (PHYH), 266500 (Refsum disease) | https://www.omim.org/entry/602026 | | ClinVar | Gene: PHYH | https://www.ncbi.nlm.nih.gov/clinvar/?term=PHYH | | Gene Ontology (GO) | GO:0005506 (Fe²⁺ binding), GO:0008198 (phytanoyl-CoA dioxygenase activity), GO:0005777 (peroxisome), GO:0006629 (lipid metabolic process) | https://www.ebi.ac.uk/QuickGO/ | | STRING | 9606.ENSP00000296234 | https://string-db.org/ | | BioGRID | 112233 | https://thebiogrid.org/ | | gnomAD | PHYH | https://gnomad.broadinstitute.org/gene/ENSG00000165617 | --- ## Related Clinical & Scientific Guides * [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway) * [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway) * [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway) ## References [1] C. Gregory-Evans, A. M. Lehman, A. Mattman, M. Kirby, K. Gregory-Evans. "Identification of novel pathogenic variants in the PHYH gene and extending the phenotypic range in Refsum disease." *Ophthalmic Genetics*, 2025. https://www.semanticscholar.org/paper/8078e7e600b8acaa14e1fedb4376a34416ba8c83 [2] J. Finsterer, G. Regelsberger, T. Voigtländer. "Refsum disease due to the splice-site mutation c.135-2A>G before exon 3 of the PHYH gene, diagnosed eight years after detection of retinitis pigmentosa." *Journal of Neurological Sciences*, 2008. https://www.semanticscholar.org/paper/c45df3fef60cb6f5fe674991450de3c0bb8daecd [3] J. Finsterer, G. Regelsberger, T. Voigtländer. "Short communication Refsum disease due to the splice-site mutation c.135-2ANG before exon 3 of the PHYH gene, diagnosed eight years after detection of retinitis pigmentosa." *Scientific Publication*, 2008. https://www.semanticscholar.org/paper/d72c6d91b2b1dc9f50e00553f258540a162b27c6 [4] M. Daich Varela, E. Schiff, S. Malka, G. Wright, O. Mahroo, A. Webster, M. Michaelides, G. Arno. "PHYH c.678+5G>T Leads to In-Frame Exon Skipping and Is Associated With Attenuated Refsum Disease." *Investigative Ophthalmology and Visual Science*, 2024. https://www.semanticscholar.org/paper/74f7859f85d2a143865b1cce8f9f66ed8a788a1e [5] Z. Qiu, G. Zezhi, J. Lei, Q. He, J. Pan, A. Ying. "Prognostic role of PHYH for overall survival (OS) in clear cell renal cell carcinoma (ccRCC)." *European Journal of Medical Research*, 2020. https://www.semanticscholar.org/paper/7d0cf1022e8e0473d262a87c692f7d53e50e5386 [6] 姚斌, 杨培龙, 黄火清, 李中媛, 罗会颖, 石鹏君, 柏映国, 孟昆, 袁铁铮. "Low-temperature neutral phytase PhyH with double structure domains as well as gene and application thereof." *Scientific Publication*, 2011. https://www.semanticscholar.org/paper/29b1f36ca44cff7ec464e72eeec552f1406f5f63 [7] T. Reiter, E. Jagoda, T. D. Capellini. "Dietary Variation and Evolution of Gene Copy Number among Dog Breeds." *PLoS ONE*, 2016. https://www.semanticscholar.org/paper/498fc51e61b1daba7ba35802c4e7e90fe0a20645 [8] X. Tian, S. Li, D. Cheng, D. Tong, T. Zhou, L. Yi, Y. Zhang, S. Lü. "Identification of the key regulatory network and genes highly associated with the synthesis of cantharidin in Epicauta chinensis by transcriptome and metabolome analyses." *Insect Science*, 2025. https://www.semanticscholar.org/paper/1afde89f69bfea25d20e41f0dbc84e4b0b53601d [9] L. Hucko, N. F. D. da Cruz, P. Kemp, C. E. Mendoza-Santiesteban, A. M. Berrocal. "Bilateral Iris and Chorioretinal Colobomas in a Child With Suspected Lamb-Shaffer Syndrome." *Ophthalmic Surgery Lasers and Imaging Retina*, 2025. https://www.semanticscholar.org/paper/fb837a2db324c5a1408f30427cca60bfbfdfb314 [10] B. Deng, Y. Liu, P. He, N. Wang, L. Xu, J. Ma. "Shared molecular features and potential diagnostic biomarkers between ulcerative colitis and sarcopenia: an integrative bioinformatics analysis with preliminary experimental validation." *Frontiers in Immunology*, 2026. https://www.semanticscholar.org/paper/8fe7dccacc3cd0657fffee20d30110b11e0e06aa [11] G. Jansen, R. Oftnan, S. Ferdinandusse, L. Ijlst, A. Muijsers, O. Skjeldal, O. Stokke, C. Jakobs, G. Besley, J. Wraith, R. Wanders. "Refsum disease is caused by mutations in the phytanoyl–CoA hydroxylase gene." *Nature Genetics*, 1997. https://www.semanticscholar.org/paper/766df03fc1de65dff6fe820b1a4dfde64a082e10 [12] G. Jansen, E. Hogenhout, S. Ferdinandusse, H. Waterham, R. Ofman, C. Jakobs, O. H. Skjeldal, R. J. Wanders. "Human phytanoyl-CoA hydroxylase: resolution of the gene structure and the molecular basis of Refsum's disease." *Human Molecular Genetics*, 2000. https://www.semanticscholar.org/paper/f6275239d6264b77405f62d2d6e3f684a61586ee [13] J. Soh, D. Kwon, Y. Cha. "Hepatic Gene Expression Profiles Are Altered by Dietary Unsalted Korean Fermented Soybean (Chongkukjang) Consumption in Mice with Diet-Induced Obesity." *Journal of Nutrition and Metabolism*, 2011. https://www.semanticscholar.org/paper/66c68d674f246ab979794c08ef4481d2a2dbb602 [14] X. Wang, C. Fang, H. He, H. Cao, L. Liu, L. Jiang, Y. Ma, W. Liu. "Identification of Key Genes in Sheep Fat Tail Evolution Based on RNA-seq." *Gene*, 2021. https://www.semanticscholar.org/paper/09aeb83660f9e124c18613628451f7af1a435b11 [15] D. M. van den Brink, P. Brites, J. Haasjes, A. Wierzbicki, J. Mitchell, M. Lambert-Hamill, J. de Belleroche, G. Jansen, H. Waterham, R. J. Wanders. "Identification of PEX7 as the second gene involved in Refsum disease." *American Journal of Human Genetics*, 2003. https://www.semanticscholar.org/paper/b61ceeded899ed1e6a94cb47b76091992330539c [16] A. Oláh, B. Németh, C